DPC-083. Anti-HIV, reverse transcriptase inhibitor

Drugs of the Future

Volumn 27, Issue 4, 2002, Pages 331-338

  Sorbera, L A ^a   Del Fresno, M ^a   Leeson, P A ^a   Silvestre, J ^a   Rabasseda, X ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; 6 CHLORO 4 (2 CYCLOPROPYLVINYL) 4 (TRIFLUOROMETHYL) 3,4 DIHYDRO 1H QUINAZOLIN 2 ONE; CALANOLIDE A; CAPRAVIRINE; DAPIVIRINE; DELAVIRDINE; EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; MIV 150; MV 0206048; MV 026048; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; R 14768; RNA DIRECTED DNA POLYMERASE INHIBITOR; SP 1093V; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG INFORMATION; DRUG PROTEIN BINDING; DRUG PURITY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; RASH; REVIEW; VERTIGO; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 0036284216     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.04.668445     Document Type: Review

References (37)

1. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors
2. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1
3. A new asymmetric 1,4-addition method: Application to the synthesis of the HIV non-nucleoside reverse transcriptase inhibitor DPC 961
4. Acute human immunodeficiency virus type 1 infection
5. Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients
6. In vitro selection for different mutational patterns in the HIV 1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097
7. Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase
8. A phase II, multi-center randomized, open label study to compare the anti-retroviral activity and tolerability of efavirenz (EFV) + indinavir (IDV), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV + 3TC at >36 weeks [DMP 266-006]
9. Virologic resistance to efavirenz
10. Second generation NNRTIs active against clinically relevant mutant variants of HIV-1 containing K103N
11. Potent antiviral activity of second generation NNRTIs DPC 961 and DPC 083 against group M and group 0 strains of HIV-1
12. Second generation NNRTIs require multiple mutations for selection of highly resistant HIV in vitro
13. Column selection and method development for the determination of the enantiomeric purity of investigational non-nucleoside reverse transcriptase inhibitors
14. Detection of a polymeric impurity in DPC 083 by thin layer chromatography
15. Sodium lauryl sulfate-catalyzed degradation of DPC 083 in solid state
16. Pharmacokinetics of a second-generation NNRTI, DPC 083, after multiple oral doses in healthy volunteers
17. Study DPC-083-203, a phase II comparison of 100 and 200 mg once-daily DPC 083 and 2 NRTIs in patients failing a NNRTI-containing regimen
18. Study DPC 083-201: A phase II double-blind (DB) comparison of 3 once daily doses of the NNRTI DPC 083 vs 600 mg efavirenz (EFV) in combination with 2 NRTIs in HIV anti-retroviral (ARV) treatment-naïve patients
19. Pyrimidine thioethers: A novel class of HIV-1 reverse transcriptase inhibitors with activity against BHAP-resistant HIV
20. Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine
21. (-)-6-Chloro-2-[(1-furo[2,3-c]pyridin-5-ylethyl)thio]-4-pyrimidinamine, PNU-142721, a new broad spectrum HIV 1 non-nucleoside reverse transcriptase inhibitor
22. Impact of mutation, plasma protein binding and pharmacokinetics on clinical efficacy of the HIV-1 non nucleoside reverse transcriptase inhibitor, DMP 266
23. TMC120 (R147681), a next-generation NNRTI, has potent in vitro activity against NNRTI-resistant HIV variants
24. R165335-TMC125, a novel non nucleoside reverse transcriptase inhibitor (NNRTI) with nanomolar activity against NNRTI resistant HIV strains
25. In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor
26. Asymmetric synthesis of 1,3-dioxolane-pyrimidine nucleosides and their anti-HIV activity
27. Characterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4-2217
28. Ingenol derivatives are highly potent and selective inhibitors of HIV replication in vitro
29. Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus
30. N-[2-(1-Cyclohexenyl)-ethyl]-N′-[2-(5-bromopyridyl)]-thiourea and N′-[2-(1-cyclohexenyl)ethyl]-N′-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1
31. N′-[2-(2-Thiophene)ethyl]-N′-[2-(5-bromopyridyl) thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1